ArticleNews reportPHN-06262026-11-02 12:27 CT

Tampa healthcare company bets big on 6 unapproved peptides after federal policy shift

Source · TBBW

TLDR

Tampa-based DataMEDS AI announced a supply agreement for six unapproved peptides following an Oct. 30 federal policy change allowing limited compounding while FDA review continues. The company says its subsidiary plans to begin filling prescriptions in November, with access to a network of more than 6,500 independent pharmacies.

01—Key points

01The agreement covers BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax; their proposed applications remain unproven.
02The HHS policy does not grant FDA approval and includes testing, prescription, labeling and safety-reporting requirements.
03DataMEDS has not disclosed financial terms or projected revenue; pharmacy participation remains unclear.

Why it matters Editorial

The agreement represents a commercial move into prescription channels for experimental peptides while FDA review and safety questions remain unresolved.

Read the original at TBBW↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.